lasofoxifene has been researched along with Bone Fractures in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armstrong, RA; Cummings, SR; Delmas, PD; Eastell, R; Ensrud, K; Goldstein, S; Kendler, D; LaCroix, AZ; Lee, A; Neven, P; Powles, T; Reid, DM; Sriram, U; Thompson, DD; Thompson, J; Vukicevic, S; Zanchetta, J | 1 |
| Becker, C | 1 |
| Andreu, JL; Silva-Fernández, L | 1 |
| Armstrong, R; Barrett-Connor, E; Cauley, J; Cummings, S; Eastell, R; Ensrud, K; LaCroix, A; Reid, DM; Thompson, DD; Thompson, JR; Vukicevic, S; Welty, F | 1 |
| Allred, DC; Armstrong, R; Cummings, SR; Curto, M; Eastell, R; Ensrud, KE; Goss, P; LaCroix, AZ; Lee, A; Neven, P; Osborne, CK; Powles, T; Reid, DM; Thompson, DD; Thompson, JR; Vukicevic, S; Wolter, K | 1 |
| Vogel, VG | 1 |
| Schmidt, C | 1 |
| Chines, AA; Komm, BS | 1 |
| Hadji, P | 1 |
2 review(s) available for lasofoxifene and Bone Fractures
| Article | Year |
|---|---|
An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis.
Topics: Bone Density Conservation Agents; Breast; Endometrium; Female; Fractures, Bone; Humans; Indoles; Osteoporosis, Postmenopausal; Piperidines; Pyrrolidines; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes | 2012 |
The evolution of selective estrogen receptor modulators in osteoporosis therapy.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Endometrial Neoplasms; Female; Fractures, Bone; Hot Flashes; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Tetrahydronaphthalenes | 2012 |
3 trial(s) available for lasofoxifene and Bone Fractures
| Article | Year |
|---|---|
Lasofoxifene in postmenopausal women with osteoporosis.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Receptors, Estrogen; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke; Tetrahydronaphthalenes; Venous Thromboembolism | 2010 |
Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Endpoint Determination; Female; Follow-Up Studies; Fractures, Bone; Humans; Incidence; Longitudinal Studies; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Receptors, Estrogen; Risk Factors; Stroke; Tetrahydronaphthalenes; Treatment Outcome | 2010 |
Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.
Topics: Aged; Aged, 80 and over; Anticarcinogenic Agents; Biomarkers, Tumor; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; Double-Blind Method; Estradiol; Female; Fractures, Bone; Humans; Incidence; Mammography; Middle Aged; Odds Ratio; Osteoporosis, Postmenopausal; Primary Prevention; Pyrrolidines; Receptors, Estrogen; Risk Assessment; Selective Estrogen Receptor Modulators; Sex Hormone-Binding Globulin; Tetrahydronaphthalenes; Treatment Outcome; United States | 2010 |
4 other study(ies) available for lasofoxifene and Bone Fractures
| Article | Year |
|---|---|
Another selective estrogen-receptor modulator for osteoporosis.
Topics: Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke; Tamoxifen; Tetrahydronaphthalenes; Venous Thromboembolism | 2010 |
Lasofoxifene for postmenopausal women with osteoporosis.
Topics: Aged; Bone Density Conservation Agents; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Risk; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Thromboembolism | 2010 |
Tipping the balance for the primary prevention of breast cancer.
Topics: Adult; Age Factors; Aged; Anticarcinogenic Agents; Biomarkers, Tumor; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Confounding Factors, Epidemiologic; Estradiol; Female; Fractures, Bone; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Primary Prevention; Pyrrolidines; Raloxifene Hydrochloride; Risk Assessment; Sample Size; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Treatment Outcome | 2010 |
Third-generation SERMs may face uphill battle.
Topics: Anticarcinogenic Agents; Bone Density Conservation Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; Drug Industry; Estradiol; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Indoles; Osteoporosis, Postmenopausal; Patents as Topic; Primary Prevention; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; United States; United States Food and Drug Administration | 2010 |